Rocket One Inc. 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-38803 Hoth Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 82-1553794 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1 Rockefeller Plaza , Suite 1039 New York , NY 10020 (Address of principal executive offices) (Zip Code) (646) 756-2997 (Registrant’s telephone number, including area code) Not applicable (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value HOTH The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ The number of shares of the issuer’s common stock, $0.0001 par value per share, outstanding at November 9, 2022 was 1,300,382 . Table of Contents Page No. PART I. FINANCIAL INFORMATION 1 Item 1. Financial Statements 1 Condensed Consolidated Balance Sheets as of September 30, 2022 (Unaudited) and December 31, 2021 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2022 and 2021 (Unaudited) 2 Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2022 and 2021 (Unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021 (Unaudited) 4 Notes to the Condensed Consolidated Financial Statements (Unaudited) 5 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3. Quantitative and Qualitative Disclosures About Market Risk 19 Item 4. Controls and Procedures 19 PART II. OTHER INFORMATION 20 Item 1. Legal Proceedings 20 Item 1A. Risk Factors 20 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20 Item 3. Defaults Upon Senior Securities 20 Item 4. Mine Safety Disclosures 20 Item 5. Other Information 20 Item 6. Exhibits 21 Signatures 22 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding: ● our business strategies; ● the timing of regulatory submissions; ● our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; ● risks relating to the timing and costs of clinical trials and the timing and costs of other expenses; ● risks related to market acceptance of products; ● the ultimate impact of the Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; ● intellectual property risks; ● risks associated with our reliance on third-party organizations; ● our competitive position; ● our industry environment; ● our anticipated financial and operating results, including anticipated sources of revenues; ● assumptions regarding the size of the available market, benefits of our products, product pricing and timing of product launches; ● management’s expectation with respect to future acquisitions; ● statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and ● our cash needs and financing plans. All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”) could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q. This Quarterly Report on Form 10-Q may include market data and certain industry data and forecasts, which we may obtain from internal company surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications, articles and surveys. Industry surveys, publications, consultant surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed. While we believe that such studies and publications are reliable, we have not independently verified market and industry data from third-party sources. ii PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS. HOTH THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2022 2021 (Unaudited) ASSETS Current assets Cash $ 8,935,081 $ 8,538,270 Marketable equity securities, at fair value 330,901 1,892,837 Prepaid expenses 191,424 93,972 Note receivable - current 50,000 50,000 Total current assets 9,507,406 10,575,079 Investment in joint ventures at fair value 387,400 410,000 Total assets $ 9,894,806 $ 10,985,079 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 930,925 $ 360,964 Accrued expenses 52,502 426,823 Accrued license fee - current portion 25,000 80,000 Total current liabilities 1,008,427 867,787 Accrued license fee - less current portion 275,000 235,000 Total liabilities 1,283,427 1,102,787 Commitments and contingencies - - Stockholders’ equity Preferred stock, $ 0.0001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively - - Series A Convertible Preferred Stock, $ 0.0001 par value, 5,000,000 shares designated; 0 shares issued and outstanding at September 30, 2022 and December 31, 2021 - - Common stock, $ 0.0001 par value, 3,000,000 shares authorized, 1,288,493 and 959,009 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively 129 96 Additional paid-in capital 50,182,173 43,591,773 Accumulated deficit ( 41,620,494 ) ( 33,727,163 ) Accumulated other comprehensive gain 49,571 17,586 Total stockholders' equity 8,611,379 9,882,292 Total liabilities and stockholders' equity $ 9,894,806 $ 10,985,079 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 HOTH THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Operating costs and expenses Research and development $ 1,451,280 $ 2,123,548 $ 3,370,841 $ 5,408,166 Research and development - licenses acquired (including stock-based compensation) 16,953 38,967 94,678 164,812 Compensation and related expenses (including stock-based compensation) 348,754 358,699 1,821,613 2,488,775 Professional fees (including stock-based compensation) 498,034 519,592 1,508,330 2,021,151 Rent 17,625 6,297 47,112 32,634 Other general and administrative expenses 351,767 206,093 802,080 605,787 Total operating expenses 2,684,413 3,253,196 7,644,654 10,721,325 Loss from operations ( 2,684,413 ) ( 3,253,196 ) ( 7,644,654 ) ( 10,721,325 ) Other expense Gains (losses) on marketable securities 40,774 ( 13,717 ) ( 266,908 ) ( 51,658 ) Change in fair value of investments in joint ventures - - ( 22,600 ) - Other (expense) income, net ( 592 ) ( 29,135 ) 40,831 ( 60,628 ) Total other expense 40,182 ( 42,852 ) ( 248,677 ) ( 112,286 ) Net loss $ ( 2,644,231 ) $ ( 3,296,048 ) $ ( 7,893,331 ) $ ( 10,833,611 ) Other comprehensive income Foreign currency translation adjustment 21,485 19,601 31,985 35,138 Total comprehensive loss $ ( 2,622,746 ) $ ( 3,276,447 ) $ ( 7,861,346 ) $ ( 10,798,473 ) Net loss per share applicable to common stockholders - basic and diluted $ ( 2.05 ) $ ( 3.45 ) $ ( 6.78 ) $ ( 12.44 ) Weighted average number of common shares outstanding, basic and diluted 1,288,481 955,538 1,164,174 871,062 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 2 HOTH THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED) For the Three Months Ended September 30, 2022 Common Stock Additional Paid-in Accumulated Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balance at June 30, 2022 1,288,469 $ 129 $ 50,169,819 $ ( 38,976,263 ) $ 28,086 $ 11,221,771 Stock-based compensation 24 - 12,354 - - 12,354 Foreign currency translation adjustment - - - - 21,485 21,485 Net loss - - - ( 2,644,231 ) - ( 2,644,231 ) Balance at September 30, 2022 1,288,493 $ 129 $ 50,182,173 $ ( 41,620,494 ) $ 49,571 $ 8,611,379 For the Three Months Ended September 30, 2021 Common Stock Additional Paid-in Accumulated Cumulative Translation Total Stockholders' Shares Amount Capital Deficit Adjustment Equity Balance at June 30, 2021 954,932 $ 95 $ 43,525,353 $ ( 26,951,021 ) $ 186 $ 16,574,613 Offering cost related with issuance of common stock, common stock warrants and prefunded warrants (net of offering costs of $ 1,591,600 ) - - ( 100,000 ) - - ( 100,000 ) Stock-based compensation 53 - 23,897 - - 23,897 Prepaid stock-based compensation 4,000 - 124,000 - - 124,000 Foreign currency translation adjustment - - - - 19,601 19,601 Net loss - - - ( 3,296,048 ) - ( 3,296,048 ) Balance at September 30, 2021 958,985 $ 95 $ 43,573,250 $ ( 30,247,069 ) $ 19,787 $ 13,346,063 For the Nine Months Ended September 30, 2022 Common Stock Additional Paid-in Accumulated Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balance at December 31, 2021 959,009 $ 96 $ 43,591,773 $ ( 33,727,163 ) $ 17,586 $ 9,882,292 Stock-based compensation 72 - 605,330 - - 605,330 Issuance of common stock (net of offering costs of $ 1,014,896 ) 329,412 33 5,985,070 - - 5,985,103 Foreign currency translation adjustment - - - - 31,985 31,985 Net loss - - - ( 7,893,331 ) - ( 7,893,331 ) Balance at September 30, 2022 1,288,493 $ 129 $ 50,182,173 $ ( 41,620,494 ) $ 49,571 $ 8,611,379 For the Nine Months Ended September 30, 2021 Common Stock Additional Paid-in Accumulated Cumulative Translation Total Stockholders' Shares Amount Capital Deficit Adjustment Equity Balance at December 31, 2020 537,558 $ 54 $ 24,074,348 $ ( 19,413,458 ) $ ( 15,351 ) $ 4,645,593 Issuance of common stock, common stock warrants and prefunded warrants (net of offering costs of $ 1,591,600 ) 273,079 27 13,407,605 - - 13,407,632 Issuance of common stock and warrants (net of offering costs of $ 572,500 ) 99,010 10 4,427,491 - - 4,427,501 Warrant exercise 45,069 4 359,509 - - 359,513 Stock-based compensation 269 - 1,180,297 - - 1,180,297 Prepaid stock-based compensation 4,000 - 124,000 - - 124,000 Foreign currency translation adjustment - - - - 35,138 35,138 Net loss - - - ( 10,833,611 ) - ( 10,833,611 ) Balance at September 30, 2021 958,985 $ 95 $ 43,573,250 $ ( 30,247,069 ) $ 19,787 $ 13,346,063 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 HOTH THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Nine Months Ended September 30, 2022 2021 Cash flows from operating activities Net loss $ ( 7,893,331 ) $ ( 10,833,611 ) Adjustments to reconcile net loss to net cash used in operating activities: Research and development-acquired license, expensed 51,500 82,500 Change in fair value of investments in joint ventures 22,600 - Stock-based compensation 605,330 1,180,297 Amortization of prepaid stock-based compensation - 16,533 Realized loss on marketable securities 194,179 41,798 Unrealized loss on marketable securities 132,063 37,843 Loss on foreign currency exchange - 60,628 Changes in operating assets and liabilities: Prepaid expenses ( 105,428 ) ( 54,740 ) Accounts payable 245,296 1,280,821 Net cash used in operating activities ( 6,747,791 ) ( 8,187,931 ) Cash flows from investing activities Purchase of research and development licenses ( 66,500 ) ( 99,500 ) Purchase of marketable securities - ( 2,556,126 ) Sale of marketable securities 1,235,694 2,507,750 Net cash provided by (used in) investing activities 1,169,194 ( 147,876 ) Cash flows from financing activities Proceeds from issuance common stock, common stock warrants and prefunded warrants, net of offering cost - 13,407,632 Proceeds from issuance common stock and warrants, net of offering cost - 4,427,501 Proceeds from issuance common stock, net of offering cost 5,985,103 - Proceeds from exercise of warrants - 359,513 Net cash provided by financing activities 5,985,103 18,194,646 Effect of exchange rate changes on cash and cash equivalents ( 9,695 ) ( 43,130 ) Net change in cash 406,506 9,858,839 Cash, beginning of period 8,538,270 2,629,670 Cash, end of period $ 8,935,081 $ 12,445,379 Non-cash investing and financing activities Prepaid stock-based compensation $ - $ 124,000 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 HOTH THERAPEUTICS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1-Organization and description of business operations Hoth Therapeutics, Inc. (together with its wholly owned subsidiary, Hoth Therapeutics Australia Pty Ltd., the “Company”) was incorporated under the laws of the State of Nevada on May 16, 2017. The Company is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing (i) a topical formulation for treating side effects from drugs used for the treatment of cancer; (ii) a treatment for mast-cell derived cancers and anaphylaxis; (iii) a treatment for traumatic brain injury and ischemic stroke; and (iv) a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The Company also has assets being developed for (i) atopic dermatitis (also known as eczema); (ii) a treatment for asthma and allergies using inhalational administration; and (iii) a treatment for inflammatory bowel diseases. In addition, the Company is developing a diagnostic device via a mobile device. The Company also has interests in certain other assets being developed by third parties (See Note 6 for a discussion of the Company’s agreement with Zylö Therapeutics, Inc. and Voltron Therapeutics, Inc.). Liquidity and capital resources Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements - Going Concern , requires management to evaluate the Company’s ability to continue as a going concern one year beyond the filing date of the given financial statements. This evaluation requires management to perform two steps. First, management must evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern. Second, if management concludes that substantial doubt is raised, management is required to consider whether it has plans in place to alleviate that doubt. Disclosures in the notes to the consolidated financial statements are required if management concludes that substantial doubt exists or that its plans alleviate the substantial doubt that was raised. The Company has funded its operations from proceeds from the sale of equity and debt securities. The Company will require significant additional capital to make the investments it needs to execute its longer-term business plan. The Company’s ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, even if it were successful, future equity issuances may result in dilution to its existing shareholders and future debt securities may contain covenants that limit the Company’s operations or ability to enter into certain transactions. The Company believes current cash is sufficient to fund operations for at least the next 12 months from the date of these financial statements. However, the Company will need to raise additional funding, through strategic relationships, public or private equity or debt financings, grants or other arrangements, to develop and seek regulatory approvals for the Company’s current and future product candidates. If such funding is not available, or not available on terms acceptable to the Company, the Company’s current development plan and plans for expansion of its general and administrative infrastructure may be curtailed. On April 14, 2022, the Company closed an underwritten public offering of 329,412 shares of the Company’s common stock at a price to the public of $ 21.25 per share (the “Offering Price”). Pursuant to the terms of an underwriting agreement dated April 11, 2022 between the Company and EF Hutton, division of Benchmark Investments, LLC, as representative of the several underwriters (the “Underwriters”), the Company granted the Underwriters a 45-day option to purchase up to an additional 49,412 shares of the Company’s common stock to cover over-allotments, if any, at the Offering Price less the underwriting discounts and commissions. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company, were $ 6.0 million. The Underwriters did not exercise their over-allotment option. Reverse Stock Split On October 20, 2022, the Company filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-25 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock. The Reverse Stock Split became effective on October 26, 2022. Shareholders who otherwise would have been entitled to receive fractional shares of common stock had their holdings rounded up to the next whole share. All references to common stock, convertible preferred stock conversion ratio, warrants to purchase common stock, options to purchase common stock, restricted stock units, restricted stock awards, share data, per share data and related information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. 5 HOTH THERAPEUTICS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 2-Significant accounting policies Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. These unaudited interim condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on March 30, 2022. The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company’s wholly owned subsidiary, Hoth Therapeutics Australia Pty Ltd, which was incorporated under the laws of the State of Victoria in Australia on June 5, 2019. All significant intercompany balances and transactions have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s condensed consolidated financial statements relate to stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the SEC on March 30, 2022. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurements , approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature. Fair Value Measurement FASB ASC 820, Fair Value Measurements , provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. 6 HOTH THERAPEUTICS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Fair value option - Note receivable The guidance in ASC 825, Financial Instruments , provides a fair value option election that allows entities to make an irrevocable election of fair value as the initial and subsequent measurement attribute for certain eligible financial assets and liabilities. Unrealized gains and losses on items for which the fair value option has been elected are reported in earnings. The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an entire instrument and is irrevocable once elected. Assets and liabilities measured at fair value pursuant to this guidance are required to be reported separately in the Company’s consolidated balance sheets from those instruments using another accounting method. Investment in joint ventures Ownership interests in entities for which the Company has significant influence that are not consolidated are accounted for as equity method investments. SEC Staff Announcement: Accounting for Limited Partnership Investments (codified in ASC 323-30-S99-1) guidance requires the use of the equity method unless the investor’s interest “is so minor that the limited partner may have virtually no influence over partnership operating and financial policies.” The SEC staff’s position is that investments in limited partnerships of greater than 3 % to 5 % are considered more than minor and, therefore, should be accounted for using the equity method or fair value option. Investments accounted for using the equity method may be reported on a lag up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity method as of the current reporting date. The determination of whether an investee’s results are recorded on a lag is made on an investment-by-investment basis. This investment in joint ventures is further described in Note of 6 these consolidated financial statements. Net loss per share Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Since the Company had a net loss in the periods presented, basic and diluted net loss per common share are the same. The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company’s net loss: As of September 30, Potentially dilutive securities 2022 2021 Warrants 402,840 402,840 Options 104,651 52,851 Non-vested restricted stock awards 36 124 Total 507,527 455,815 7 HOTH THERAPEUTICS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Recent accounting pronouncements Currently, management does not believe that any other recently issued, but not yet effective accounting pronouncements, if currently adopted, would have a material impact on the Company’s condensed consolidated financial statements. Note 3-License agreements The following summarizes the Company’s research and development expenses for licenses acquired (including stock-based compensation) during three and nine months ended September 30, 2022 and 2021: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 The George Washington University $ 16,953 $ 22,551 $ 57,178 $ 82,312 Isoprene Pharmaceuticals, Inc. - 15,000 - 15,000 North Carolina State University - - 20,000 30,000 Virginia Commonwealth University - 30,000 10,000 30,000 University of Cincinnati - - 7,500 7,500 Adjustment - ( 28,584 ) - - $ 16,953 $ 38,967 $ 94,678 $ 164,812 The George Washington University During the three and nine months ended September 30, 2022, the Company recorded an expense of approximately $ 12,000 and $ 43,000 , respectively, related to warrants granted to The George Washington University pursuant to a patent license agreement. The Company also recorded $ 5,000 and $ 14,000 during the three and nine months ended September 30, 2022, respectively, for a license maintenance fee. North Carolina State University During the three and nine months ended September 30, 2022, the Company paid $ 0 and $ 20,000 for a license fee, respectively. Virginia Commonwealth University On May 18, 2020, the Company entered into an Exclusive License Agreement with the Virginia Commonwealth University Intellectual Property Foundation, as amended on June 22, 2022. Pursuant to such agreement, the Company accrued $ 275,000 for five years of annual minimum payments and $ 25,000 for annual maintenance fees. During the three and nine months ended September 30, 2022, the Company paid $ 0 and $ 10,000 , respectively, for a license fee. University of Cincinnati During the three and nine months ended September 30, 2022, the Company paid $ 0 and $ 7,500 , respectively, for a license fee. 8 HOTH THERAPEUTICS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 4-Note Receivable Pursuant to the sublicense agreement dated July 30, 2020 by and between the Company and Isoprene Pharmaceuticals, Inc. (“Isoprene”), the Company made an investment of $ 50,000 in Isoprene in the form of a convertible promissory note (the “Isoprene Note”) on September 10, 2020. The Isoprene Note was due to mature on September 10, 2022 and accrues interest at a rate equal to the lower of: (i) the highest lawful rate permitted under applicable law and (ii) 6 % per annum. The Isoprene Note may not be prepaid without the prior written consent of the Company; provided , however , that if the Isoprene Note has not been converted in connection with a Qualified Financing (as defined herein) or Change of Control (as defined in the Isoprene Note) by the two year anniversary of the date of the issuance of the Isoprene Note, Isoprene may elect, in its sole discretion, to repay the Isoprene Note and any accrued interest thereon. In the event a Qualified Financing occurs before the Isoprene Note is repaid in full on the maturity date or the conversion of such note pursuant to a Change of Control, the Isoprene Note may be converted into such number of convertible preferred stock issued in the Qualified Financing equal to the balance of such note divided by the Capped Conversion Price. “Qualified Financing” means the first sale of Isoprene’s convertible preferred stock in a private financing that results in gross proceeds of at least $5 million. “Capped Conversion Price” means the lesser of (i) the per share or unit price in the Qualified Financing and (ii) an amount determined by dividing (A) $15 million by (B) the fully diluted capitalization of Isoprene immediately prior to the conversion of the Isoprene Note. In the event a Change of Control occurs before the Isoprene Note is repaid in full on the maturity date or the conversion of such note pursuant to a Qualified Financing, the Isoprene Note may be converted into such number of shares of Isoprene’s common stock equal to the quotient obtained by dividing (i) the balance of the Isoprene Note by (ii) two times the fair market value of a share of Isoprene common stock as set for in the acquisition agreement pertaining to such Change of Control. As of the maturity date of the Isoprene Note, neither a Qualified Financing nor a Change of Control had occurred. As such, as of September 30, 2022, the Isoprene Note was deemed a receivable of the Company. The Isoprene Note and accrued interest was paid off on October 21, 2022. Note 5-Investments in Marketable Securities The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and nine months ended September 30, 2022 and 2021, which are recorded as a component of other (expense) income, net on the condensed consolidated statements of operations and comprehensive loss, are as follows: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Unrealized gain (loss) $ 26,572 $ 9,566 $ ( 132,063 ) $ ( 37,843 ) Realized loss - ( 41,214 ) ( 194,179 ) ( 41,798 ) Dividend income 14,202 17,931 59,334 27,983 $ 40,774 $ ( 13,717 ) $ ( 266,908 ) $ ( 51,658 ) Note 6-Fair Value of Financial Assets and Liabilities The following table presents the Company’s assets and liabilities that are measured at fair value at September 30, 2022 and December 31, 2021: Fair value measured at September 30, 2022 Total at September 30, Quoted prices in active markets Significant other observable inputs Significant unobservable inputs 2022 (Level 1) (Level 2) (Level 3) Assets Marketable securities - mutual funds $ 330,901 $ 330,901 $ - $ - Investment in joint ventures $ 387,400 $ - $ - $ 387,400 Note receivable - current $ 50,000 $ - $ - $ 50,000 Fair value measured at December 31, 2021 Total at December 31, Quoted prices in active markets Significant other observable inputs Significant unobservable inputs 2021 (Level 1) (Level 2) (Level 3) Assets Marketable securities - mutual funds $ 1,892,837 $ 1,892,837 $ - $ - Investment in joint ventures $ 410,000 - - $ 410,000 Note receivable - current $ 50,000 - - $ 50,000 9 HOTH THERAPEUTICS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Level 3 Measurement The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis: Investment in joint ventures at fair value at December 31, 2021 $ 410,000 Change in fair value of investments in joint ventures ( 22,600 ) Investment in joint ventures at fair value at September 30, 2022 $ 387,400 Investment in joint ventures The Company has elected to measure the investment in joint ventures using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivative due to change in the fair value will be reflected in interest income and other, net in the consolidated statements of operations. The value at which the Company’s investment in joint ventures is carried on its books is adjusted to estimated fair value at the end of each quarter, taking into account general economic and stock market conditions and those characteristics specific to the underlying investments. Investment in HaloVax On March 23, 2020, the Company entered into a Development and Royalty Agreement (the “Development and Royalty Agreement”) with Voltron Therapeutics, Inc. (“Voltron”) to form a joint venture entity named HaloVax, LLC (“HaloVax”) to jointly develop potential product candidates for the prevention of COVID-19 based upon certain technology that had been exclusively licensed by Voltron from The General Hospital Corporation (d/b/a Massachusetts General Hospital). Pursuant to the Development and Royalty Agreement, the Company is entitled to receive sales-based royalties. In addition, pursuant to the terms of the Development and Royalty Agreement, on March 23, 2020, the Company and HaloVax entered into a Membership Interest Purchase Agreement pursuant to which the Company purchased 5 % of HaloVax’s outstanding membership interests for $ 250,000 on March 27, 2020 (the “Initial Closing Date”) and had the option to purchase up to an additional 25 % of HaloVax’s membership interests (for $ 3,000,000 (inclusive of the $ 250,000 )), which option expired 30 days after the Initial Closing Date. On May 28, 2020, the Company entered into a Membership Interest Purchase Agreement to purchase 1 % of HaloVax’s outstanding membership interest for a purchase price of $ 100,000 . No change in fair value occurred during the nine months ended September 30, 2022. The investment in HaloVax was valued $ 350,000 as of September 30, 2022 and December 31, 2021. Investment in Zylö In connection with the Company’s March 2020 underwritten public offering of shares of its common stock, on May 4, 2020, the Company purchased 120,000 shares of Zylö’s Class B common stock for $ 60,000 . No change in fair value occurred during the nine months ended September 30, 2022. On December 8, 2021, the Company entered into a third amendment (the “Zylö Amendment”) to the Exclusive Sublicense Agreement with Zylö originally dated August 19, 2019, pursuant to which the Company licensed its novel cannabinoid therapeutic, HT-005 for lupus patients, back to Zylö. Pursuant to the Zylö Amendment, on December 6, 2021, Zylö issued the Company 100,000 shares of its Class B common stock. In addition, pursuant to the Zylö Amendment, within 90 days following a sale by Zylö of all of its assets and rights related to HT-005 to a third-party (a “Sale”), Zylö shall pay the Company a low single digit percent of the net proceeds received by it attributable to HT-005 in the United States and Canada and their respective territories (collectively, the “Territory”) for the purposes of therapeutic uses related to lupus in humans (the “Field”). After the Sale, any and all rights of the Company pursuant to the Exclusive Sublicense Agreement, including all amendments thereto, shall terminate. Furthermore, pursuant to the Zylö Amendment, following the date of the first commercial sale of HT-005 in the Territory, in the Field, Zylö shall pay the Company (i) a low single digit percent of the Net Sales (as defined in the Exclusive Sublicense Agreement) of HT-005 in the event HT-005 is sold in the Territory and (ii) a low double digit percent of any royalty that Zylö receives through the sublicense to a third-party based on Net Sales of HT-005 in the Territory which payments shall continue in each country in the Territory until expiration of the last-to-expire Valid Claim (as defined in the Exclusive Sublicense Agreement). Zylö conducted a 409A valuation on their Class B Common shares and valued its share price at $ 0.17 per share. This value was ratified by Zylö’s board of directors in May 2022. Therefore, the Company recorded approximate $ 23,000 in unrealized loss on this investment during the second quarter of 2022. The investment in Zylö was valued at $ 37,000 and $ 60,000 as of September 30, 2022 and December 31, 2021, respectively. 10 HOTH THERAPEUTICS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note receivable As of September 30, 2022, the fair value of the Isoprene Note was measured at $ 50,000 , taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. No change in fair value was recorded during the nine months ended September 30, 2022. Note 7-Stockholders’ Equity 2018 Equity Incentive Plan The compensation committee of the board of directors increased the number of shares reserved pursuant to the Company’s 2018 Equity Incentive Plan (“2018 Plan”) by 26,878 shares effective as of January 1, 2021, such that as of January 1, 2021, the Company had an aggregate of 66,878 shares of common stock reserved for issuance pursuant to the 2018 Plan. On June 24, 2021, at the annual meeting of shareholders, shareholders of the Company approved an amendment to the 2018 Plan to further increase the number of shares reserved for issuance thereunder from 66,878 shares to 146,878 shares. On February 2, 2022, the compensation committee of the board of directors further increased the number of shares reserved for issuance under the 2018 Plan from 146,878 shares to 156,878 shares. 2022 Equity Incentive Plan On March 24, 2022, the Company’s board of directors adopted the Hoth Therapeutics, Inc. 2022 Omnibus Equity Incentive Plan (the “2022 Plan”) initially reserving 96,000 shares of the Company’s common stock for issuance thereunder. The 2022 Plan became effective on June 23, 2022 upon approval of the 2022 Plan by the Company’s shareholders at the Company’s annual meeting of shareholders. Restricted Stock Awards A summary of the Company’s restricted stock awards granted under the 2018 Plan during the nine months ended September 30, 2022 is as follows: Number of Restricted Stock Awards Weighted Average Grant Day Fair Value Nonvested at December 31, 2021 100 $ 75.00 Vested ( 64 ) 75.00 Nonvested at September 30, 2022 36 $ 75.00 11 HOTH THERAPEUTICS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of September 30, 2022, approximately $ 300 of unrecognized stock-based compensation expense was related to restricted stock awards. The weighted average remaining contractual terms of unvested restricted stock awards was approximately 0.26 years at September 30, 2022. Stock Options A summary of option activity under the Company’s stock option plan for nine months ended September 30, 2022 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2021 52,851 $ 84.15 $ - 8.6 Employee options issued 51,800 14.75 - 9.5 Outstanding as of September 30, 2022 104,651 $ 49.80 $ - 8.5 Options vested and exercisable as of September 30, 2022 104,651 $ 49.80 $ - 8.5 Stock Based Compensation Stock-based compensation expense for the three and nine months ended September 30, 2022 and 2021 was as follows: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Employee stock option awards $ - $ - $ 560,377 $ 1,092,428 Employee restricted stock awards 401 1,346 1,776 5,557 Non-employee restricted stock awards - 16,533 - 16,533 Non-employee stock warrant awards 11,953 22,551 43,178 82,312 $ 12,354 $ 40,430 $ 605,330 $ 1,196,830 Employee related stock-based compensation is recognized as “compensation and related expenses (including stock-based compensation)” and non-employee related stock-based compensation is recognized as “professional fees (including stock-based compensation)” or “research and development - licenses acquired (including stock-based compensation)” in the condensed consolidated statements of operations and comprehensive loss. Warrants A summary of warrant activity for the nine months ended September 30, 2022 is as follows: Number of Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2021 402,840 $ 49.83 $ - 2.3 Outstanding as of September 30, 2022 402,840 $ 49.83 $ - 1.6 Warrants exercisable as of September 30, 2022 401,312 $ 49.73 $ - 1.8 The Company has determined that the warrants should be accounted as a component of stockholders’ equity. 12 HOTH THERAPEUTICS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 8-Commitments and contingencies Office lease The Company leases office space for approximately $ 4,500 a month. Rent expense for the three months ended September 30, 2022 and 2021 was approximately $ 18,000 and $ 6,000 , respectively. Rent expense for the nine months ended September 30, 2022 and 2021 was approximately $ 47,000 and $ 33,000 , respectively. The Company is not a party to a lease that is in excess of 12 months. Litigation The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Note 9-Risk and Uncertainties The outbreak of the novel Coronavirus (COVID-19) evolved into a global pandemic. COVID-19 has spread to many regions of the world. The extent to which COVID-19 impacts the Company’s business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain COVID-19 or treat its impact, among others. As a result of the spread of COVID-19, certain aspects of the Company’s business operations have been delayed, and the Company may be subject to additional delays or interruptions. Specifically, if shelter-in-place orders and other mandated local travel restrictions are imposed, among other things, the research and development activities of certain of the Company’s partners may be affected, which may result in delays to the Company’s clinical trials, and the Company can provide no assurance as to when such trials, if delayed, will resume or the revised timeline to complete trials once resumed. Furthermore, site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. If COVID-19 continues to spread, some participants and clinical investigators may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and the Company may be unable to conduct its clinical trials. Further, COVID-19 continues to spread and the Company’s operations are adversely impacted, the Company risks a delay, default and/or nonperformance under its existing agreements which may increase its costs. These cost increases may not be fully recoverable or adequately covered by insurance. Moreover, infections and deaths related to COVID-19 may disrupt the healthcare and healthcare regulatory systems in both the United States and globally, including in Australia. Such disruptions could divert healthcare resources away from, or materially delay review and/or approval with respect to the Company’s clinical trials by the U.S. Food and Drug Administration and foreign regulatory authorities, including the Belberry Human Research Ethics Committee in Australia. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of the Company’s clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of the Company’s product candidates. The Company currently utilizes third parties to, among other things, manufacture raw materials. If any third-party in the supply chain for materials used in the production of the Company’s product candidates are adversely impacted by restrictions resulting from the ongoing COVID-19 outbreak, the Company’s supply chain may be disrupted, limiting the Company’s ability to manufacture its product candidates for its clinical trials and research and development. 13 HOTH THERAPEUTICS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The spread of COVID-19, which caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material economic effect on the Company’s business. While the potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, it has already caused, and may result in further disruption of global financial markets, which may negatively impact the Company’s ability to access capital on favorable terms, if at all. In addition, a recession, depression or other sustained adverse market event resulting from the spread of COVID-19 could materially and adversely affect the Company’s business and the value of its common stock. The ultimate impact of the ongoing COVID-19 pandemic, or any other health epidemic, is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, its clinical trials, its research programs, healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s operations, and the Company will continue to monitor the situation closely. Note 10-Subsequent events The Company evaluates events that have occurred after the balance sheet date through the date for which the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements except as set forth herein. On November 2, 2022, the Company filed a Certificate of Designation of the Series B Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Nevada to create a new class of Series B Preferred Stock, par value $ 0.0001 per share (the “Series B Preferred Stock”). The Certificate of Designation designates 2,000,000 shares of authorized preferred stock as Series B Preferred Stock. The Series B Preferred Stock are not entitled to receive dividends or any other distributions. The Series B Preferred Stock are entitled to ten votes per share and shall vote together with the Company’s issued and outstanding shares of common stock as a single class exclusively with respect to the Authorized Stock Increase (as defined in the Certificate of Designation). The Series B Preferred Stock have no rights as to any distribution or assets of the Company upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company. The outstanding shares of Series B Preferred Stock shall be redeemed in whole, but not in part for an aggregate price of $ 10 (i) if such redemption is ordered by the Company’s board of directors, in its sole discretion, or (ii) automatically and effective immediately after the effectiveness of the Authorized Stock Increase. On November 2, 2022, the Company entered into a Subscription and Investment Representation Agreement with an investor pursuant to which the Company issued and sold 2,000,000 shares of its newly designated Series B Preferred Stock to such purchaser for an aggregate purchase price of $1,000. On November 10, 2022, the Company entered into a Third Amendment (the “Amendment”) to Employment Agreement by and between the Company and Stefanie Johns, the Company’s Chief Scientific Officer, originally dated August 28, 2020, as amended on January 29, 2021 and June 25, 2021. Pursuant to the Amendment, among other things, the term of Dr. Johns’ employment shall be for a period of no more than six months from the date of the Amendment; provided, however, the Company or Dr. Johns may terminate Dr. Johns’ employment prior to the expiration of such six month period for any reason upon 10 days prior notice. In addition, Dr. Johns shall no longer be eligible to receive any annual bonus or equity awards. Furthermore, pursuant to the Amendment, upon separation of Dr. Johns’ employment from the Company for any reason, the Company shall provide Dr. Johns with all accrued but unpaid compensation earned through her final day of employment, all accrued but unused vacation and reimbursement of all documented, unreimbursed expenses incurred prior to her separation. Moreover, upon Dr. Johns’ execution of a release of claims after her final day of employment, as set forth in the Amendment, the Company shall provide Dr. Johns with certain benefits as set forth therein. 14 ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as may be amended, supplemented or superseded from time to time by other reports we file with the SEC. All amounts in this report are in U.S. dollars, unless otherwise noted. Overview We are a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. We are focused on developing (i) a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); (ii) a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); (iii) a treatment for traumatic brain injury and ischemic stroke (HT-TBI); and (iv) a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). We also have assets being developed for (i) atopic dermatitis (also known as eczema) (BioLexa); (ii) a treatment for asthma and allergies using inhalational administration (HT-004); and (iii) a treatment for acne as well as inflammatory bowel diseases (HT-003). In addition, we are continuing to evaluate a novel peptide that may be used to slow the transmission of SARS-CoV-2 (HT-002). We are also developing a diagnostic device via a mobile device. Furthermore, we have interests in certain other assets being developed by third parties including a treatment for patients with lupus that is being developed by Zylö Therapeutics, Inc. and potential product candidates being developed pursuant to our agreement with Voltron Therapeutics, Inc. for the prevention of COVID-19. Recent Developments On October 20, 2022, we filed a Certificate of Change with the Secretary of State of the State of Nevada to effectuate a 1-for-25 reverse stock split (the “Reverse Stock Split”) of our issued and outstanding and authorized shares of common stock. The Reverse Stock Split became effective on October 26, 2022, and shareholders who otherwise would have been entitled to receive fractional shares of common stock had their holdings rounded up to the next whole share. On November 2, 2022, we filed a Certificate of Designation of the Series B Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Nevada to create a new class of Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”). The Certificate of Designation designates 2,000,000 shares of authorized preferred stock as Series B Preferred Stock. The Series B Preferred Stock are not entitled to receive dividends or any other distributions. The Series B Preferred Stock are entitled to ten votes per share and shall vote together with our issued and outstanding shares of common stock as a single class exclusively with respect to the Authorized Stock Increase (as defined in the Certificate of Designation). The Series B Preferred Stock have no rights as to any distribution or assets of our Company upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of our Company. The outstanding shares of Series B Preferred Stock shall be redeemed in whole, but not in part for an aggregate price of $10 (i) if such redemption is ordered by our board of directors, in its sole discretion, or (ii) automatically and effective immediately after the effectiveness of the Authorized Stock Increase. On November 2, 2022, we entered into a Subscription and Investment Representation Agreement with an investor pursuant to which we issued and sold 2,000,000 shares of our newly designated Series B Preferred Stock to such purchaser for an aggregate purchase price of $1,000. 15 Results of Operations Comparison of the Three Months Ended September 30, 2022 and 2021 Operating Costs and Expenses Research and Development Expenses During the three months ended September 30, 2022, we incurred research and development expenses of approximately $1.5 million as compared to approximately $2.2 million during the three months ended September 30, 2021. The approximately $0.7 million decrease was primarily attributed to the decreased number of research and development activities undertaken by us during the three months ended September 30, 2022. We expect our research and development activities to increase as we develop our existing product candidates and potentially acquire new product candidates, reflecting increasing costs associated with the following: ● employee-related expenses, which include salaries and benefits, and rent expenses; ● fees related to in-licensed products and technology; ● expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct our clinical trials and a substantial portion of our pre-clinical activities; ● costs of acquiring and manufacturing clinical trial materials; and ● costs associated with non-clinical activities and regulatory approvals. Compensation, Professional Fees, Rent and Other (“General and Administrative Expenses”) During the three months ended September 30, 2022, we incurred General and Administrative Expenses of approximately $1.2 million as compared to approximately $1.1 million during the three months ended September 30, 2021. The approximately $0.1 million increase was primarily attributed to an increase in professional fees. We anticipate that our General and Administrative Expenses will increase in future periods, reflecting continued and increasing costs associated with: ● support of our research and development activities; ● stock compensation granted to key employees and non-employees; ● support of business development activities; and ● increased professional fees and other costs associated with the regulatory requirements. Comparison of the Nine Months Ended September 30, 2022 and 2021 Operating Costs and Expenses Research and Development Expenses During the nine months ended September 30, 2022, we incurred research and development expenses of approximately $3.5 million as compared to approximately $5.6 million during the nine months ended September 30, 2021. The approximately $2.1 million decrease was primarily attributed to the decreased number of research and development activities undertaken by us during the nine months ended September 30, 2022. 16 We expect our research and development activities to increase as we develop our existing product candidates and potentially acquire new product candidates, reflecting increasing costs associated with the following: ● employee-related expenses, which include salaries and benefits, and rent expenses; ● fees related to in-licensed products and technology; ● expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct our clinical trials and a substantial portion of our pre-clinical activities; ● costs of acquiring and manufacturing clinical trial materials; and ● costs associated with non-clinical activities and regulatory approvals. General and Administrative Expenses During the nine months ended September 30, 2022, we incurred General and Administrative Expenses of approximately $4.2 million as compared to approximately $5.1 million during the nine months ended September 30, 2021. The approximately $0.9 million decrease was primarily attributed to a decrease in professional fees and compensation and related expenses. Specifically, the fair value of options granted to our officers and directors during the nine months ended September 30, 2022 decreased by approximately $0.4 million as compared September 30, 2021. We anticipate that our General and Administrative Expenses will increase in future periods, reflecting continued and increasing costs associated with: ● support of our research and development activities; ● stock compensation granted to key employees and non-employees; ● support of business development activities; and ● increased professional fees and other costs associated with the regulatory requirements. Liquidity and Capital Resources To date we have funded our operations primarily through the sale of equity and debt securities. As of September 30, 2022, we had approximately $8.9 million in cash, marketable securities of approximately $0.3 million, working capital of approximately $8.5 million and an accumulated deficit of approximately $41.6 million. Net cash used in operating activities was $6.7 million and $8.2 million for the nine months ended September 30, 2022 and 2021, respectively. We incurred losses of approximately $7.9 million and $10.8 million for the nine months ended September 30, 2022 and 2021, respectively. We have incurred substantial operating losses since inception and expect to continue to incur significant operating losses for the foreseeable future as we continue our pre-clinical and clinical development of our product candidates. We have not yet commercialized any products and have never generated any revenue from product sales. We believe that our existing cash as of September 30, 2022 will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date of this Quarterly Report on Form 10-Q. We have entered into certain license, sublicense, sponsored research and option agreements with third parties. Pursuant to such agreements, we may be required to make certain: (i) license maintenance fee payments; (ii) out-of-pocket expense payments, including, but not limited to, payments related to intellectual property and research related expenses; (iii) development and commercialization expense payments; (iv) annual and quarterly minimum payments; (v) diligence expense payments; and (vi) revenue interest payments. In addition, subject to the achievement of certain development and/or commercialization events, we may also be required to make certain: (i) minimum royalty payments, ranging from middle to high five figures, (ii) sales-based royalties and running royalties, ranging from low single digits to low double digits; and (iii) milestone payments, of up to approximately $17 million (if all milestones in all of our current agreements are achieved). 17 Additional funding will be necessary to fund our future clinical and pre-clinical activities. We may obtain additional financing through sales of our equity and debt securities or entering into strategic partnership arrangements, or a combination of the foregoing. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all, particularly in light of the economic downturn and uncertainty related to the COVID-19 pandemic. If we are unable to secure adequate additional funding as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates. In addition, the magnitude and duration of the COVID-19 pandemic and its impact on our liquidity and future funding requirements is uncertain as of the filing date of this Quarterly Report on Form 10-Q, as the COVID-19 pandemic continues to evolve globally. Cash Flows from Operating Activities For the nine months ended September 30, 2022, net cash used in operations was approximately $6.7 million, which primarily resulted from a net loss of approximately $7.9 million and changes in operating assets and liabilities of approximately $0.1 million, partially offset by approximately $0.6 million in stock-based compensation, $0.2 million realized loss on marketable securities and $0.1 million unrealized loss on marketable securities. For the nine months ended September 30, 2021, net cash used in operations was approximately $8.2 million, which primarily resulted from a net loss of approximately $10.8 million, and was partially offset by changes in operating assets and liabilities of approximately $1.2 million and approximately $1.2 million stock-based compensation. Cash Flows from Investing Activities For the nine months ended September 30, 2022, net cash provided by investing activities was approximately $1.2 million which was primarily related to the sale of marketable securities. For the nine months ended September 30, 2021, net cash provided used in investing activities was approximately $0.1 million, which was primarily related to the sale of marketable securities of approximately $2.5 million, and was partially offset by the purchase of marketable securities of approximately $2.6 million. Cash Flows from Financing Activities For the nine months ended September 30, 2022, net cash provided by financing activities was approximately $6.0 million, which primarily resulted from net proceeds from the issuance of common stock. For the nine months ended September 30, 2021, net cash provided by financing activities was approximately $18.2 million, which was primarily resulted from net proceeds from the issuance of common stock, warrants and pre-funded warrants. Critical Accounting Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts and related disclosures in the financial statements. Management considers an accounting estimate to be critical if: ● it requires assumptions to be made that were uncertain at the time the estimate was made; and ● changes in the estimate or different estimates that could have been selected could have material impact in our results of operations or financial condition. While we base our estimates and judgments on our experience and on various other factors that we believe to be reasonable under the circumstances, actual results could differ from those estimates and the differences could be material. See Note 2 to our condensed consolidated financial statements for a discussion of our significant accounting policies. Recently Issued Accounting Standards Not Yet Effective or Adopted Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements. 18 JOBS Act On April 5, 2012, the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies provided under the JOBS Act. As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates for complying with new or revised accounting standards. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including, without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of our initial public offering; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act. ITEM 4. CONTROLS AND PROCEDURES. Evaluation of Disclosure Controls and Procedures Our principal executive officer and principal financial officer, after evaluating the effectiveness of the Company’s “disclosure controls and procedures” (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) as of September 30, 2022, the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that our disclosure controls and procedures were effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding disclosure. Changes in Internal Control There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Limitations on Effectiveness of Controls and Procedures In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. 19 PART II - OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS. From time to time, we may be subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition. ITEM 1A. RISK FACTORS. Risk factors that affect our business and financial results are discussed in Part I, Item 1A “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 30, 2022 (“Annual Report”). There have been no material changes in our risk factors from those previously disclosed in our Annual Report. You should carefully consider the risks described in our Annual Report, which could materially affect our business, financial condition or future results. The risks described in our Annual Report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. If any of the risks actually occur, our business, financial condition, and/or results of operations could be negatively affected. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. During the three months ended September 30, 2022, the Company issued an aggregate of 72 shares of the Company’s common stock, which shares were subject to a vesting schedule, to members of the Company’s board of directors for services. The foregoing issuances were exempt from registration under Section 4(a)(2) of the Securities Act. ITEM 3. DEFAULTS UPON SENIOR SECURITIES. None. ITEM 4. MINE SAFETY DISCLOSURES. Not applicable. ITEM 5. OTHER INFORMATION. On November 10, 2022, the Company entered into a Third Amendment (the “Amendment”) to Employment Agreement by and between the Company and Stefanie Johns, the Company’s Chief Scientific Officer, originally dated August 28, 2020, as amended on January 29, 2021 and June 25, 2021. Pursuant to the Amendment, among other things, the term of Dr. Johns’ employment shall be for a period of no more than six months from the date of the Amendment; provided, however, the Company or Dr. Johns may terminate Dr. Johns’ employment prior to the expiration of such six month period for any reason upon 10 days prior notice. In addition, Dr. Johns shall no longer be eligible to receive any annual bonus or equity awards. Furthermore, pursuant to the Amendment, upon separation of Dr. Johns’ employment from the Company for any reason, the Company shall provide Dr. Johns with all accrued but unpaid compensation earned through her final day of employment, all accrued but unused vacation and reimbursement of all documented, unreimbursed expenses incurred prior to her separation. Moreover, upon Dr. Johns’ execution of a release of claims after her final day of employment, as set forth in the Amendment, the Company shall provide Dr. Johns with certain benefits as set forth therein. 20 ITEM 6. EXHIBITS. Exhibit No. Description 3.1 Amendment to the Amended and Restated Bylaws of Hoth Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 22, 2022) 10.1*+ Third Amendment to Employment Agreement by and between the Company and Stefanie Johns dated November 10, 2022 31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1** Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2** Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS* Inline XBRL Instance Document 101.SCH* Inline XBRL Taxonomy Extension Schema Document 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document 104* Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 is formatted in Inline XBRL * Filed herewith. ** Furnished herewith. + Indicates a management contract or any compensatory plan, contract or arrangement. 21 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. HOTH THERAPEUTICS, INC. Date: November 10, 2022 By: /s/ Robb Knie Robb Knie, Chief Executive Officer (Principal Executive Officer) Date: November 10, 2022 By: /s/ David Briones David Briones, Chief Financial Officer (Principal Financial and Accounting Officer) 22